// App-Quantinova.ai

184 : Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.

Researchers

Presenter

  • Johann Sebastian De Bono

Principal Investigators

  • Matthew Raymond Smith

  • Fred Saad

  • Mary Beth Todd

  • Thomas W. Griffin

  • Eric Jay Small

  • Neal D. Shore

  • Karim Fizazi

  • Peter De Porre

  • Thian San Kheoh

  • Jinhui Li

  • Charles J. Ryan

  • Dana E. Rathkopf

  • Peter F.A. Mulders

Medical Centers

  • Radboud University Medical Center, Njmegen, Netherlands

  • Institut Gustave Roussy, Universite Paris-Sud, Paris, France

  • University of Montreal, Montreal, QC, Canada

  • Carolina Urologic Research Center, Myrtle Beach, SCJanssen Research and Development, Los Angeles, CAJanssen Global Services, Raritan, NJ

  • Janssen Research & Development, Beerse, Belgium

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Johnson & Johnson Medical China, Shanghai, China

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Massachusetts General Hospital, Boston, MA

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Locations

  • Canada

  • China

  • Netherlands

  • United Kingdom

  • United States

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • taxane

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved